To the full analysis
Ultragenyx Pharmaceutical stock: Returns and Performance
RAREUltragenyx Pharmaceutical's share price fell by 14.9% a year over the last 10 years, 80.2% in total.
This shows what Ultragenyx Pharmaceutical Inc. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 13 Nov 2026
1 year
−51.5%
since 12 Nov 2025
5 years
−27.4%
a year, −79.8% in total
10 years
−14.9%
a year, −80.2% in total
Since 2014
−7.2%
a year, −61.5% in total
Returns by period
| Period | Total | Per year |
|---|---|---|
| 1 year | −51.5% | −51.5% |
| 3 years | −53.4% | −22.5% |
| 5 years | −79.8% | −27.4% |
| 10 years | −80.2% | −14.9% |
| Since 2014 | −61.5% | −7.2% |
Returns by calendar year
Figures as a table
| Year | Return |
|---|---|
| 2026 to date | −29.3% |
| 2025 | −45.3% |
| 2024 | −12% |
| 2023 | +3.2% |
| 2022 | −44.9% |
| 2021 | −39.3% |
| 2020 | +224.1% |
| 2019 | −1.8% |
| 2018 | −6.3% |
| 2017 | −34% |
| 2016 | −37.3% |
| 2015 | +155.7% |
Peak price and largest drawdown
All-time high
$177.39
on 23 Dec 2020, today 90.8% below
Largest drawdown
−92.7%
from the high on 23 Dec 2020 to the low on 16 Sep 2026, the high has not been regained yet
This is the pure share price return in US dollars from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.